Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™)
Phase 2a Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™) In Cystic Fibrosis Patients With Chronic Infections Due To Pseudomonas Aeruginosa.
Sponsor: Insmed Incorporated
Listed as NCT00777296, this PHASE1/PHASE2 trial focuses on Cystic Fibrosis and remains completed. Sponsored by Insmed Incorporated, it has been updated 9 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
▶ Show 4 earlier versions
-
Aug 2019 — Aug 2020 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Aug 2019 [monthly]
Completed PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1_PHASE2
First recorded
Feb 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Insmed Incorporated
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Belgrade, Serbia , Bratislava, Slovakia , Budapest, Hungary , Kaposvár, Hungary , Kharkiv, Ukraine , Kiev, Ukraine , Košice, Slovakia , Leuven, Belgium , Rabka-Zdrój, Poland , Skopje, North Macedonia and 1 more location